Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome
Status:
Completed
Trial end date:
2017-12-18
Target enrollment:
Participant gender:
Summary
Metabolic syndrome increases the risk for development of heart disease. Another condition
associated with metabolic syndrome is fatty liver disease which is also referred to as
nonalcoholic fatty liver disease (NAFLD). Recently, drugs that block fatty acid synthesis
have been developed to treat cancer. These drugs are now being considered for the treatment
of NAFLD. A research test designed to measure liver fatty acid synthesis involves consumption
of a sugary solution and measurement of blood fats over a six-hour period. The present study
will test the drug 3-V Bioscience-2640 in healthy subjects with characteristics of the
metabolic syndrome before and after 10 days of treatment to determine if 50 mg/d
significantly reduces liver fat synthesis and lowers liver fat storage.